Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
about
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.
P2860
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Evaluating Expected Costs and ...... in Non-Small-Cell Lung Cancer.
@en
type
label
Evaluating Expected Costs and ...... in Non-Small-Cell Lung Cancer.
@en
prefLabel
Evaluating Expected Costs and ...... in Non-Small-Cell Lung Cancer.
@en
P2093
P1433
P1476
Evaluating Expected Costs and ...... in Non-Small-Cell Lung Cancer.
@en
P2093
Dana P Goldman
Jacquelyn W Chou
Joanna P MacEwan
Mark T Linthicum
P304
P356
10.1001/JAMAONCOL.2015.0203
P577
2015-05-01T00:00:00Z